Abstract
Over the past decade, the capacity of cancer cells to oscillate between epithelial and mesenchymal phenotypes, termed epithelial plasticity (EP), has been demonstrated to play a critical role in metastasis. This phenomenon may be particularly important for prostate cancer (PC) progression, since recent studies have revealed interplay between EP and signaling by the androgen receptor (AR) oncoprotein. Moreover, EP appears to play a role in dictating the response to therapies for metastatic PC. This review will evaluate preclinical and clinical evidence for the relevance of EP in PC progression and consider the potential of targeting and measuring EP as a means to treat and manage lethal forms of the disease.
Original language | English |
---|---|
Pages (from-to) | 643-651 |
Number of pages | 9 |
Journal | Trends in Molecular Medicine |
Volume | 20 |
Issue number | 11 |
DOIs | |
Publication status | Published - 1 Nov 2014 |
Externally published | Yes |
Keywords
- Androgen deprivation therapy
- Androgen receptor
- Chemotherapy
- Epithelial plasticity
- Epithelial-mesenchymal transition
- Mesenchymal-epithelial transition